Skip navigation
Agenda

Stay on the Pulse of Federal and State Reporting Requirements, Policy Initiatives and Strategic Best Practices for Implementation

September 18-19, 2019
  • Philadelphia, PA

Agenda

Want more agenda details? Download the brochure.

CHOOSE BETWEEN TWO PRE-CONFERENCE WORKSHOPS (A-B) WEDNESDAY, SEPTEMBER 18, 2019

A.Drug Pricing Transparency Bootcamp —
Key Considerations and Learnings For Reporting

12:30

Workshop Registration

1:30

Workshop Leader’s Opening Remarks

Workshop Objective:

As drug pricing transparency continues to remain in the news headlines, an increasing number of people are beginning to witness its impact. Join experts for a high-level overview of the highlights and critical requirements of drug pricing transparency the industry is facing today. Whether you are new to the topic, or just need a refresher, this pre-conference workshop offers key insights into this hot button issue.

Workshop Outline:

I. Assess the Current Drug Pricing Transparency Landscape

II. TRAILBLAZER TALK Analyze the Implementation and Enforcement of California and Oregon Transparency Laws

III.Navigate Reporting Templates and Drafting Plans

Workshop Leader:

Trevor L. Wear
Partner
Sidley Austin LLP

Jack Chen
Associate
Sidley Austin LLP

There will be a 30 minute networking and refreshment break at 3:00

B. Strategize for 2020 —
Breaking Down Transparency Headlines for Industry

12:30

Workshop Registration

1:30

Workshop Leader’s Opening Remarks

Workshop Objective:

Even for those more seasoned in drug pricing transparency, there is still uncertainty that exists as the transparency legislation continues to evolve. Continuous requirements are surfacing at both a state and federal level, creating more complexity. Join industry colleagues to break down the rulings in the headlines today from the trenches, scenario plan for the future and determine how to strategize for 2020.

Workshop Outline:

I. Navigate the Status of State Transparency Legislations

II. Assess Various Outcomes of Federal Rulings

III. SCENARIO PLANNING Prepare Action Steps for the Future

Workshop Leaders:

John Linehan
Member of the Firm
Epstein Becker Green

Christopher Smith
Senior Counsel,
Epstein Becker Green

There will be a 30 minute networking and refreshment break at 3:00

5:00

Close of Workshops and Day One

Networking, Wine and
Cheese Reception
immediately following the conclusion of the day one workshops

MAIN CONFERENCE Thursday, September 19, 2019

7:15

Conference Registration and Continental Breakfast

8:00

Chairperson’s Welcome and Opening Remarks

William Harris
Assistant General Counsel
Sanofi

8:15

The Ideal Drug Pricing Bill? — Leveraging Elements in
Multiple Drug Pricing Bills for a Better Functioning Market

Saumil Pandya
Deputy Vice President, Advocacy & Strategic Alliances
Pharmaceutical Research and Manufacturers of America (PhRMA)

8:45

State Drug Pricing Transparency Level-Set —
Reporting and Requirements Landscape

John Oroho
Executive Vice President, Chief Strategy Officer
Porzio Life Sciences, LLC

9:30

FEDERAL SPOTLIGHT Status Update on Federal Initiatives for Transparency

Bill Sarraille
Partner
Sidley Austin LLP

10:15

Networking and Refreshment Break

10:45

State-by-State Analysis Showcase

This state-by-state analysis showcase shines a spotlight on states that have established regulations and/or guidance. Join industry experts to dive into the nuances of new, updated, and future requirements and reporting regulations that will potentially affect drug pricing transparency as we move into 2020.

I. Status Report — Evaluate New State Legislations

Trevor L. Wear
Partner
Sidley Austin LLP

II. Update on Existing Transparency Laws

Rujul Desai
Counsel
Covington & Burling LLP

Thomas Felton
Senior Corporate Counsel
Celgene

12:45

Networking Luncheon

1:45

FORECASTING FOR THE FUTURE Anticipate New State Legislations to Watch in 2020 —
A Practical Analysis

Merlin Brittenham
Senior Director, Law
Pharmaceutical Research and Manufacturers of America (PhRMA)

Mallory O’Connor
Director of Public Policy
Mallinckrodt Pharmaceuticals

2:30

INDUSTRY PULSE Benchmarking Survey Results Revealed

Alyson L. Wooten, PharmD, JD, MBA
Associate Director
Berkeley Research Group

Austin Hay
Managing Consultant
Berkeley Research Group

3:15

Networking and Refreshment Break

3:45

Industry Talk —
Set up an Internal Team to Respond to Drug Pricing Transparency Laws

Conversation Contributors:

Sheea Sybblis
Senior Counsel
Boehringer Ingelheim

William Harris
Assistant General Counsel
Sanofi

Brian Bohnenkamp
Partner, FDA and Life Sciences Practice
King & Spalding LLP

4:30

Examine Trade Secret Protections for Compliance

Brian Bohnenkamp
Partner, FDA and Life Sciences Practice
King & Spalding LLP

5:15

Close of Conference

Agenda

Want more agenda details? Download the brochure.

Want more agenda details? Download the brochure.

CHOOSE BETWEEN TWO PRE-CONFERENCE WORKSHOPS (A-B) WEDNESDAY, SEPTEMBER 18, 2019

A.Drug Pricing Transparency Bootcamp —
Key Considerations and Learnings For Reporting

12:30

Workshop Registration

1:30

Workshop Leader’s Opening Remarks

Workshop Objective:

As drug pricing transparency continues to remain in the news headlines, an increasing number of people are beginning to witness its impact. Join experts for a high-level overview of the highlights and critical requirements of drug pricing transparency the industry is facing today. Whether you are new to the topic, or just need a refresher, this pre-conference workshop offers key insights into this hot button issue.

Workshop Outline:

I. Assess the Current Drug Pricing Transparency Landscape

II. TRAILBLAZER TALK Analyze the Implementation and Enforcement of California and Oregon Transparency Laws

III.Navigate Reporting Templates and Drafting Plans

Workshop Leader:

Trevor L. Wear
Partner
Sidley Austin LLP

Jack Chen
Associate
Sidley Austin LLP

There will be a 30 minute networking and refreshment break at 3:00

B. Strategize for 2020 —
Breaking Down Transparency Headlines for Industry

12:30

Workshop Registration

1:30

Workshop Leader’s Opening Remarks

Workshop Objective:

Even for those more seasoned in drug pricing transparency, there is still uncertainty that exists as the transparency legislation continues to evolve. Continuous requirements are surfacing at both a state and federal level, creating more complexity. Join industry colleagues to break down the rulings in the headlines today from the trenches, scenario plan for the future and determine how to strategize for 2020.

Workshop Outline:

I. Navigate the Status of State Transparency Legislations

II. Assess Various Outcomes of Federal Rulings

III. SCENARIO PLANNING Prepare Action Steps for the Future

Workshop Leaders:

John Linehan
Member of the Firm
Epstein Becker Green

Christopher Smith
Senior Counsel,
Epstein Becker Green

There will be a 30 minute networking and refreshment break at 3:00

5:00

Close of Workshops and Day One

Networking, Wine and
Cheese Reception
immediately following the conclusion of the day one workshops

MAIN CONFERENCE Thursday, September 19, 2019

7:15

Conference Registration and Continental Breakfast

8:00

Chairperson’s Welcome and Opening Remarks

William Harris
Assistant General Counsel
Sanofi

8:15

The Ideal Drug Pricing Bill? — Leveraging Elements in
Multiple Drug Pricing Bills for a Better Functioning Market

Saumil Pandya
Deputy Vice President, Advocacy & Strategic Alliances
Pharmaceutical Research and Manufacturers of America (PhRMA)

8:45

State Drug Pricing Transparency Level-Set —
Reporting and Requirements Landscape

John Oroho
Executive Vice President, Chief Strategy Officer
Porzio Life Sciences, LLC

9:30

FEDERAL SPOTLIGHT Status Update on Federal Initiatives for Transparency

Bill Sarraille
Partner
Sidley Austin LLP

10:15

Networking and Refreshment Break

10:45

State-by-State Analysis Showcase

This state-by-state analysis showcase shines a spotlight on states that have established regulations and/or guidance. Join industry experts to dive into the nuances of new, updated, and future requirements and reporting regulations that will potentially affect drug pricing transparency as we move into 2020.

I. Status Report — Evaluate New State Legislations

Trevor L. Wear
Partner
Sidley Austin LLP

II. Update on Existing Transparency Laws

Rujul Desai
Counsel
Covington & Burling LLP

Thomas Felton
Senior Corporate Counsel
Celgene

12:45

Networking Luncheon

1:45

FORECASTING FOR THE FUTURE Anticipate New State Legislations to Watch in 2020 —
A Practical Analysis

Merlin Brittenham
Senior Director, Law
Pharmaceutical Research and Manufacturers of America (PhRMA)

Mallory O’Connor
Director of Public Policy
Mallinckrodt Pharmaceuticals

2:30

INDUSTRY PULSE Benchmarking Survey Results Revealed

Alyson L. Wooten, PharmD, JD, MBA
Associate Director
Berkeley Research Group

Austin Hay
Managing Consultant
Berkeley Research Group

3:15

Networking and Refreshment Break

3:45

Industry Talk —
Set up an Internal Team to Respond to Drug Pricing Transparency Laws

Conversation Contributors:

Sheea Sybblis
Senior Counsel
Boehringer Ingelheim

William Harris
Assistant General Counsel
Sanofi

Brian Bohnenkamp
Partner, FDA and Life Sciences Practice
King & Spalding LLP

4:30

Examine Trade Secret Protections for Compliance

Brian Bohnenkamp
Partner, FDA and Life Sciences Practice
King & Spalding LLP

5:15

Close of Conference